Inventing New Possibilities, Transforming Treatment Paradigms

Otology Labs is a clinical stage biopharmaceutical company developing novel therapeutics to treat disease in powerful new ways, which harness proven approved drugs to target bone remodelling that selectively targets disease causing ear diseases with the goal of slowing down or reversing conductive hearing loss. We are developing therapeutics with transformative new modality, “targeted ear diseases”, with the ability to provide drug platforms with slow and prolonged release to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with diseases in the early or post operative stages. Our team has developed a proprietary drug management platform called Otrix that enables the design of highly specialized broad class of molecules with leading ability to track compliance across all regulatory bodies internationally, our tool let's you continuously ensure your device or drug meets all necessary regulations and tracks for any changes automatically using AI. .

Otology Labs is owned and led by a proven parent private VC with many market available drugs. Our team are dedicated scientists and drug hunters, with decades of experience in the foundational areas of bone sciences and inner ear drug development.